Showing results (421-430 of 530) with videos related to

Sort By:
Pageof 53
The Journal of Antimicrobial Chemotherapy|March 28, 2025
Population pharmacokinetics and exposure-response relationship of the antituberculosis drug BTZ-043Simon E Koele, Norbert Heinrich, Veronique R De Jager, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 7, 2024
Diagnostic accuracy of TB screening tests in a prospective multinational cohort: Chest-X-ray with computer-aided detection, Xpert TB host response, and C-reactive proteinRebecca Crowder, Balamugesh Thangakunam, Alfred Andama, et al.
Antimicrobial Agents and Chemotherapy|September 28, 2023
Drug interaction potential of high-dose rifampicin in patients with pulmonary tuberculosisRalf Stemkens, Veronique de Jager, Rodney Dawson, et al.
The New England Journal of Medicine|March 14, 2019
A Trial of a Shorter Regimen for Rifampin-Resistant TuberculosisAndrew J Nunn, Patrick P J Phillips, Sarah K Meredith, et al.
BMC Infectious Diseases|August 17, 2017
Outcomes from patients with presumed drug resistant tuberculosis in five reference centers in BrazilD M P Ramalho, P F C Miranda, M K Andrade, et al.
BMC Medicine|March 30, 2018
Liver toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor Duncan Tweed, Genevieve Helen Wills, Angela M Crook, et al.
Implementation Science : IS|August 14, 2020
Protocol for the 3HP Options Trial: a hybrid type 3 implementation-effectiveness randomized trial of delivery strategies for short-course tuberculosis preventive therapy among people living with HIV in UgandaJillian L Kadota, Allan Musinguzi, Juliet Nabunje, et al.
BMC Infectious Diseases|July 13, 2018
Toxicity associated with tuberculosis chemotherapy in the REMoxTB studyConor D Tweed, Angela M Crook, Evans I Amukoye, et al.
American Journal of Respiratory and Critical Care Medicine|February 6, 2015
A dose-ranging trial to optimize the dose of rifampin in the treatment of tuberculosisMartin J Boeree, Andreas H Diacon, Rodney Dawson, et al.
Plos Medicine|December 16, 2021
Completion of isoniazid-rifapentine (3HP) for tuberculosis prevention among people living with HIV: Interim analysis of a hybrid type 3 effectiveness-implementation randomized trialFred C Semitala, Jillian L Kadota, Allan Musinguzi, et al.
Pageof 53